Early Phase Myeloma Studies
description
Transcript of Early Phase Myeloma Studies
![Page 1: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/1.jpg)
Early Phase Myeloma Studies
Rakesh Popat
UCL Cancer Institute & University College Hospital
![Page 2: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/2.jpg)
Myeloma outcomes getting better…
Kumar et al., Blood 2007Kumar et al, Leukemia 2011
…but not good enough
![Page 3: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/3.jpg)
Why develop early phase trials in the UK?
• Improve patient access to novel agents• Provide evidence to develop clinically relevant
treatments for the UK• Influence drug development globally• Advance understanding of myeloma and drug
resistance• Investigate treatment specific predictors and markers
of response/ resistance
![Page 4: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/4.jpg)
Early phase clinical trials: the risks
![Page 5: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/5.jpg)
An approach to early phase trials
Early Phase
Clinical Trial
Academia
Scientific question
Pharma
Novel drug(s)
Biomarker Evaluation
Biological
Markers of
Activity
Trial Management
Clinical Trial
Network
![Page 6: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/6.jpg)
Myeloma Treatments under evaluation
Mahindra, A. et al. (2012); Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.15
![Page 7: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/7.jpg)
UK Myeloma Phase I/II Studies Overview
ACADEMIC PIPELINECOMMERCIAL
C16006MLN9708+MP
MUK 6
VTD-Pana
MUK 3
CHR3996+
Tosedostat
TY
PE
1st L
INE
RE
LA
PS
E
MUK 5
CVD vsCCarD
PADIMAC CARDAMON
DARATUMUMAB
+Rev Dex
+Vel Dex
MUK 4VelDex
+Vorinostat
Vel Dex±
Tabalumab
![Page 8: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/8.jpg)
Proteasome Inhibitors
K Anderson, ASH Education Book December 2011
![Page 9: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/9.jpg)
Can we defer high dose treatment in people that have responded well?
New Diagnosis
PAD (2-6 cycles)
≥ VGPRPR
High Dose Melphalan
High Dose Melphalan
Observe
Relapse
VelcadeDoxorubicinDexamethasone
PAD =
<PR
Salvage
Re-inductionStem cell harvestMRD
![Page 10: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/10.jpg)
PADIMAC
![Page 11: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/11.jpg)
MLN9708 with melphalan & prednisolone (phase 1/2)
INDUCTION 12 cyclesINDUCTION 12 cycles
Days 1 4 8 15 22 28
MLN9708
Melphalan
Prednisolone
MAINTENANCE up to 1yrMAINTENANCE up to 1yr
Days 1 8 15 22 28
• Newly diagnosed
• Not suitable for ASCT
• Newly diagnosed
• Not suitable for ASCT
MLN9708
![Page 12: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/12.jpg)
MUK 5 (phase 2)CVD vs CCD
Randomisation
CVD8 cycles 21 days
CCarD6 cycles 28 days
MaintenanceCarfilzomib
Up to 18 months
No maintenance
• 1st relapse or refractory to 1 line of therapy
• IMW Measurable disease
• 1st relapse or refractory to 1 line of therapy
• IMW Measurable disease
![Page 13: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/13.jpg)
Proteasome and HDAC Inhibition
Hideshima T et al. Mol Cancer Ther 2011;10:2034-2042
![Page 14: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/14.jpg)
MUK 6 (Phase 1/2)VTD-Panabinostat
INDUCTION 16 cyclesINDUCTION 16 cycles
Days 1 3 5 8 10 12 21
Bortezomib
Dexamethasone
Panabinostat
Thalidomide
Panabinostat
MAINTENANCE up to 1yrMAINTENANCE up to 1yr
• 1- 4 prior lines• Prior BZ ok if
responsive• Measurable
disease (IMW criteria)
• 1- 4 prior lines• Prior BZ ok if
responsive• Measurable
disease (IMW criteria)
![Page 15: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/15.jpg)
MUK 3 (Phase 1/2)CHR3996 + Tosedostat
Faith Davies Lab
![Page 16: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/16.jpg)
Monoclonal Antibody Targets
![Page 17: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/17.jpg)
Tabalumab
Neri P et al. Clin Cancer Res 2007;13:5903-5909
![Page 18: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/18.jpg)
Bortezomib +/- Tabalumab Phase 2
![Page 19: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/19.jpg)
Daratumumab
Daratumumab Fact SheetWeers et al; The Journal of Immunology 2011;186(3) 1840-1848
![Page 20: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/20.jpg)
Plesner et al., ASH 2012
![Page 21: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/21.jpg)
Daratumumab & lenalidomide
van der Veer M S et al. Haematologica 2011;96:284-290
GEN503: A Phase 1/2 trial investigating the safety of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma
GEN503: A Phase 1/2 trial investigating the safety of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma
![Page 22: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/22.jpg)
B Cell Receptor Signalling
Young & Staudt, Nature Reviews Drug Discovery 12, 229-243 (March 2013)
• Ag induced aggregation of BCR – recruitment of SYC• SYC phosphorylates BLNK – BTK – CARD11• CD19 activates PI3K• Result activation of survival pathways
![Page 23: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/23.jpg)
Pathogenesis of Lymphoma
![Page 24: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/24.jpg)
BCR signalling in lymphoid malignancy
Young & Staudt, Nature Reviews Drug Discovery 12, 229-243 (March 2013)
• ABC DLBCL• FL• CLL• MCL• MAL
• Burkitts• GCB DLBCL
![Page 25: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/25.jpg)
Targeting the BCR
Weistner et al, Journal of Clinical Oncology, Vol 30, 2012Young & Staudt, Nature Reviews Drug Discovery 12, 229-243 (March 2013)
![Page 26: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/26.jpg)
Ibrutinib & Myeloma
Edwards C M Blood 2012;120:1757-1759Tai et al. Blood 2012;120(9):1877-1887.
(1) directly inhibit tumor growth(2) directly inhibit osteoclastic bone resorption, (3) inhibit the release of osteoclast-derived tumor
growth factors(4) prevent adhesion to bone marrow stromal cells
(BMSCs) and release of BMSC-derived growth factors.
![Page 27: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/27.jpg)
Ibrutinib Combinations
Edwards C M Blood 2012;120:1757-1759Tai et al. Blood 2012;120(9):1877-1887.
![Page 28: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/28.jpg)
Ibrutinib Combinations
Yang, Y. et al. Cancer Cell 2012
• MYD88 L265P mutations cooperate with CD79B mutations to enhance BCR signaling addiction
• ABC DLBCLs with CARD11 mutations or MYD88 L265P without CD79B mutation resist ibrutinib
• MYD88 L265P mutations cooperate with CD79B mutations to enhance BCR signaling addiction
• ABC DLBCLs with CARD11 mutations or MYD88 L265P without CD79B mutation resist ibrutinib
![Page 29: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/29.jpg)
BCR inhibitor Myeloma Early Phase Trial
![Page 30: Early Phase Myeloma Studies](https://reader036.fdocuments.us/reader036/viewer/2022062500/5681598b550346895dc6d1df/html5/thumbnails/30.jpg)
Summary
• Number of early phase myeloma studies in UK• Mix of commercial and academically sponsored• Novel drug access to patients improving• To be globally competitive:
– Crucial to maintain innovative pipeline– Meet ambitious recruitment targets– Improve trial set up times